16 results on '"Lindman, Henrik"'
Search Results
2. Current treatment landscape of HR+/HER2− advanced breast cancer in the Nordics: a modified Delphi study.
3. Use of classifiers to optimise the identification and characterisation of metastatic breast cancer in a nationwide administrative registry
4. Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1
5. Good adherence to adjuvant endocrine therapy in early breast cancer – a population-based study based on the Swedish Prescribed Drug Register
6. U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden
7. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
8. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)
9. Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1
10. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
11. Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer
12. A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in Sweden
13. Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis?
14. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)
15. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
16. FEC Mobilized Stem Cells for High-dose Therapy in Breast Cancer Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.